Service of Neurology, University Hospital, "Marqués de Valdecilla", 39008 Santander, Spain.
Expert Rev Neurother. 2001 Sep;1(1):20-7. doi: 10.1586/14737175.1.1.20.
Currently available oral triptans are not ideal, at least for 20-30% of migraine patients, due to either response failure or adverse events. Almotriptan is a novel selective 5-HT1B/D receptor agonist exhibiting the highest bioavailability among triptans, both outside and within a migraine attack. The tolerability of the therapeutic oral dose of almotriptan, 12.5 mg, is similar to that of placebo, with a remarkably low incidence of chest symptoms. At this dose, efficacy parameters remain comparable to those of sumatriptan 100 mg, while the recurrence rate is in the lower range. This balanced profile makes almotriptan 12.5 mg a good choice for the symptomatic treatment of the typical migraine patient.
目前可用的口服曲坦类药物并不理想，至少对 20-30%的偏头痛患者而言，这要么是因为治疗反应失败，要么是因为不良反应。阿莫曲坦是一种新型的选择性 5-HT1B/D 受体激动剂，在偏头痛发作内外，其生物利用度均为曲坦类药物中最高。阿莫曲坦 12.5 毫克的治疗口服剂量的耐受性与安慰剂相似，胸部症状的发生率非常低。在此剂量下，疗效参数与舒马曲坦 100 毫克相当，而复发率处于较低水平。这种平衡的特征使阿莫曲坦 12.5 毫克成为典型偏头痛患者症状治疗的一个不错选择。
